Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials
复制标题
DOI：
10.1161/circulationaha.109.906479
复制
发表时间：
2010-03-09
期刊：
影响因子：
37.8
通讯作者：
Ridker, Paul M.
中科院分区：
文献类型：
--
作者：
Mora, Samia;Glynn, Robert J.;Ridker, Paul M.
背景：鉴于其益处证据不足，他汀类药物对无心血管疾病 (CVD) 的女性的治疗存在争议。我们在“使用他汀类药物进行预防的理由：评估瑞舒伐他汀的干预试验”(JUPITER) 中分析了性别特异性结果，并综合了之前试验的结果。方法和结果 - JUPITER 参与者包括 6801 名 60 岁以上的女性和 11 001 名 50 岁以上的男性，其高敏 C 反应蛋白 >= 2 mg/L 和低密度脂蛋白胆固醇276 CVD 事件；平均年龄，63 至 69 岁）。使用瑞舒伐他汀和安慰剂的 JUPITER 女性的绝对 CVD 发生率（每 100 人年）（分别为 0.57 和 1.04）低于男性（分别为 0.88 和 1.54），女性（风险比，0.54；95% 置信区间，0.37 至 0.80；P=0.002）和男性（风险比， 0.58；95%置信区间，0.45至0.73；
Background-Statin therapy in women without cardiovascular disease (CVD) is controversial, given the insufficient evidence of benefit. We analyzed sex-specific outcomes in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and synthesized the results with prior trials.Methods and Results-JUPITER participants included 6801 women >= 60 years of age and 11 001 men >= 50 years of age with high-sensitivity C-reactive protein >= 2 mg/L and low-density lipoprotein cholesterol 276 CVD events; mean age, 63 to 69 years). Absolute CVD rates (per 100 person-years) in JUPITER women for rosuvastatin and placebo (0.57 and 1.04, respectively) were lower than for men (0.88 and 1.54, respectively), with similar relative risk reduction in women (hazard ratio, 0.54; 95% confidence interval, 0.37 to 0.80; P=0.002) and men (hazard ratio, 0.58; 95% confidence interval, 0.45 to 0.73; P